# First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

> **NCT05759923** · PHASE1 · RECRUITING · sponsor: **Molecure S.A.** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Ovarian Carcinoma
- Advanced Renal Cell Carcinoma
- Advanced Pancreatic Carcinoma
- Advanced Colorectal Carcinoma
- Metastatic Pancreatic Carcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Ovarian Carcinoma

## Interventions

- **DRUG:** OATD-02

## Key facts

- **NCT ID:** NCT05759923
- **Lead sponsor:** Molecure S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-26
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759923, "First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05759923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*